Tevogen Bio Holdings Inc.
TVGN
$6.97
-$0.03-0.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -32.21% | 16.63% | 30.13% | 79.87% | 427.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -51.20% | -33.15% | -26.39% | -4.53% | 505.72% |
| Operating Income | 51.20% | 33.15% | 26.39% | 4.53% | -505.72% |
| Income Before Tax | -91.41% | -292.20% | -425.62% | -91.58% | 77.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -91.41% | -292.20% | -425.62% | -91.58% | 77.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -91.41% | -292.20% | -425.62% | -91.58% | 77.30% |
| EBIT | 51.20% | 33.15% | 26.39% | 4.53% | -505.72% |
| EBITDA | 51.41% | 33.28% | 26.60% | 4.54% | -515.26% |
| EPS Basic | -101.00% | -48.08% | -53.74% | 20.94% | 86.17% |
| Normalized Basic EPS | 58.01% | 48.02% | 44.99% | 29.15% | -153.90% |
| EPS Diluted | 58.07% | 54.59% | 53.38% | 62.69% | 31.81% |
| Normalized Diluted EPS | 57.19% | 47.03% | 43.90% | 27.57% | -149.06% |
| Average Basic Shares Outstanding | 13.39% | 33.31% | 42.71% | 47.34% | 47.72% |
| Average Diluted Shares Outstanding | 12.39% | 31.93% | 41.08% | 45.51% | 49.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |